The Filing Desk

Annovis Bio

ANVS · NYSE · Health Care · Financials, fiscal 2019 to 2025

ANVS · Last close · November 19, 2026
$0.75
Value Annovis Bio yourself

Annovis Bio reported revenue of $0 million in fiscal 2025. The diluted share count rose 68.0%.

Annovis Bio, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 13, 2026 · 0001104659-26-027751 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$29M
 
Free cash flow
—
 
Return on equity
−220.6%
2938.5 pts
Market cap
$32M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Annovis Bio does

Annovis Bio is a drug developer working on treatments for diseases in which brain cells break down over time, such as Alzheimer's disease and Parkinson's disease. It has no products for sale. Its main drug candidate, buntanetap, is a pill designed to lower the levels of several toxic proteins that the company says damage nerve cells and their ability to communicate.

In February 2025 the company began a late-stage (Phase 3) trial of buntanetap in 760 patients with early Alzheimer's disease, with six months of treatment followed by twelve more. In January 2026 it began a longer-term study in Parkinson's patients to test the drug's safety over time, and it plans a third study in Parkinson's patients with dementia once it has more funding. It has finished 12 clinical studies so far, most of them safety studies in healthy volunteers. It relies on outside manufacturers to make the drug and on outside firms to run its trials.

Annovis has never earned revenue from selling a product. It had a net loss of $28.9 million in 2025 and ended the year with $19.5 million in cash and cash equivalents; management says there is substantial doubt it can keep operating for the next twelve months without more financing. As of February 28, 2026, it had eight full-time employees, and its offices are in Malvern, Pennsylvania.

Its biggest risks, as it describes them

  • It may not be able to keep operating unless it raises more money, and raising it could dilute existing shareholders.
  • Its heavy dependence on buntanetap, a single drug candidate that may never win approval or sell well.
  • Alzheimer's and Parkinson's drugs have had little success, and buntanetap uses a new approach.
  • Clinical trials are costly and uncertain, and good early results may not hold up in later trials.
  • Its reliance on contract manufacturers to make buntanetap and on outside firms to run its trials.
From Annovis Bio's annual report on Form 10-K, filed March 13, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Annovis Bio lost money in fiscal 2025: a net loss of $29 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments462861120
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio30.5x4.7x2.4x——
Quick ratio30.5x4.7x2.4x——
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Annovis Bio's filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Annovis Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $2.1 million of Annovis Bio shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 20, 2026Michael B HoffmanDirectorBought76,344$1.87$142,784Form 4
Apr 2, 2026Michael B HoffmanDirectorBought713,800$2.10$1.5 millionForm 4
Dec 8, 2025Michael B HoffmanDirectorBought45,000$4.31$193,800Form 4
Nov 24, 2025Michael B HoffmanDirectorBought39,200$4.08$159,886Form 4
Nov 21, 2025Michael B HoffmanDirectorBought20,000$3.50$69,900Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''−61.50——
Accruals ratio−70.2%−22.3%−18.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFail——
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Annovis Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Annovis BioFY25——————
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—000000
Revenue growth———————
Gross profit———————
Research and development13816392025
Operating income−2−7−14−26−45−27−30
Net income−1−6−14−25−56−25−29
Diluted EPS (US$)−3.51−0.87−1.90−3.10−6.23−2.31−1.40
Diluted shares (millions)068891221
Cash flow
Cash from operations−0−4−9−17−40−22−26
Capital expenditure———————
Free cash flow———————
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation0259542
Balance sheet at fiscal year end
Cash and short-term investments08462861120
Debt incl. finance leases0——————
Total assets184636101421
Total liabilities31281854
Shareholders' equity−984428−8917
Margins and ratios
Gross margin———————
Operating margin———————
Net margin———————
Free cash flow margin———————
Rule of 40 (growth + FCF margin)———————
Return on capital———————
Return on equity——−55.7%−69.6%−546.4%−3,159.1%−220.6%
Return on assets—−118.3%−53.5%−61.8%−243.2%−203.8%−164.8%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Annovis Bio's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Annovis Bio.